The new fluoride? FDA greenlights rapamycin oral health trial

Trial Evaluating Rapamycin in Periodontal Disease Receives FDA Approval – Matt Kaeberlein's Optispan for Monitoring Biomarkers of Aging.

The U.S. Food and Drug Administration has approved the first-ever study to evaluate the efficacy of rapamycin in treating periodontal disease in older adults. The RAPID clinical trial, led by Dr. Jonathan An of the University of Washington, aims to address chronic inflammatory oral diseases that affect more than 70% of the elderly by targeting the mTOR pathway with rapamycin.

Periodontal disease has long been linked to other age-related conditions, such as cardiovascular disease, diabetes and Alzheimer's disease. While current treatments involve deep cleansing, it is thought that these options may be less effective as the disease progresses. Supported by Impetus Grants and VitaDAO, the RAPID trial aims to change the treatment paradigm for periodontal disease by focusing on the underlying biological aging process rather than addressing its symptoms.

Inhibition of mTOR by rapamycin is a well-established immunomodulatory drug that was originally developed as an immunosuppressant for organ transplant patients and has shown promise in extending lifespan and healthspan in experimental animals. Following promising preclinical results, the RAPID trial aims to explore the potential of rapamycin to not only reduce, but potentially reverse, periodontal disease, providing a potential new approach to oral health management in older adults .

Optispan monitors aging biomarkers

Participants in the RAPID trial will receive a comprehensive examination, rapamycin treatment and free dental cleanings (including deep cleaning), and will be compensated for their participation.

Seattle-based longevity company Optispan is partnering on the RAPID trial. Optispan was co-founded by renowned aging researchers Dr. Matt Kaeberlein and Dr. George Haddad, whose mission is to “provide everyone with optimal health and longevity.”

Optispan co-founders Matt Kaeberlein and George Haddad.

“This trial demonstrates our commitment to proactive, science-based health care and marks a critical moment in the treatment of age-related diseases,” said Kaeberlein, a researcher at the Dog Aging Project, a Large-scale program to evaluate the effects of rapamycin in dogs.

The company's role in the RAPID trial will include monitoring biological aging biomarkers, providing insights into the broader health effects of rapamycin treatment.

“By monitoring participants' biological biomarkers of aging, our goal is to collect valuable data that could redefine the understanding and management of periodontal disease and its systemic effects,” Haddad said.

Stay tuned for our interview with Optispan's Matt Kaeberlein in the coming weeks.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *